BRAF and malignant colon neoplasm: Altogether, the obtained data point to the relevance of S1P metabolism in the development of resistance to vemurafenib and indicate that targeting S1P production by the SphK2 inhibitor ABC294640 could increase the sensitivity of BRAF mutated resistant colon cancer cells to vemurafenib.